FILE - This April 20, 2010, file photo shows an exterior view of Amgen offices in Fremont, Calif. Amgen Inc. agreed on Tuesday, Dec. 18, 2012, to pay $762 million to resolve federal litigation accusing the drugmaker of marketing the anemia treatment Aranesp for unapproved uses. (AP Photo/Paul Sakuma, File)

Associated Press
FILE - This April 20, 2010, file photo shows an exterior view of Amgen offices in Fremont, Calif. Amgen Inc. agreed  on Tuesday, Dec. 18, 2012, to pay $762 million to resolve federal litigation accusing the drugmaker of marketing the anemia treatment Aranesp for unapproved uses. (AP Photo/Paul Sakuma, File)
FILE - This April 20, 2010, file photo shows an exterior view of Amgen offices in Fremont, Calif. Amgen Inc. agreed on Tuesday, Dec. 18, 2012, to pay $762 million to resolve federal litigation accusing the drugmaker of marketing the anemia treatment Aranesp for unapproved uses. (AP Photo/Paul Sakuma, File)
View Comments (0)